AZ signs kidney drug deal with Ionis for up to $330m
Deal is result of six-year collaboration with AZ
X
AZ signs kidney drug deal with Ionis for up to $330m
https://pharmaphorum.com/news/az-buys-kidney-disease-drug-from-ionis-for-up-to-330m/
Alnylam
Alnylam halts trials of haemophilia drug after patient death
Trials will resume once safety protocols have been reviewed.
Silence Therapeutics takes rival Alnylam to court in patent fight
Silence claims late-stage drugs infringe patents.
Ionis hit by safety concerns, rivals Alnylam benefit
Biotech insists drug for rare inherited disorder is still approvable.
Alnylam plunges after deaths in rare disease trial
Biotech axes revusiran due to safety concerns.
Alnylam a ‘premier league’ addition to UK biotech
UK base will be operational HQ, Switzerland to be official head office
